1. Medtech Insight
  2. >>Business

Start-Up Spotlight: SetPoint Develops Vagus Nerve Stimulation To Treat Crohn's Disease And Rheumatoid Arthritis

 
• By Reed Miller

SetPoint Medical is developing vagus nerve stimulation technology for Crohn’s disease and rheumatoid arthritis and believes it will be a "platform technology" for treating a variety of autoimmune diseases.

Start-up Spotlight

SetPoint Medical Corp. expects to address a variety of chronic autoimmune diseases with a unique bioelectric implant.

In the early 2000s, company co-founder Kevin Tracey, a neurosurgeon at the Feinstein Institute for Medical Research near New York, identified the role of inflammatory reflex and began studying how...

With proprietary pulse parameters to stimulate the vagus nerve, SetPoint’s device can amplify the immunoregulation effect of the spleen by releasing specific neurotransmitters such as acetylcholine that bind to specific...

More from Business

More from Medtech Insight

German Bionic Launches ‘Strongest Exoskeleton To Date’

 
• By Natasha Barrow

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.

India-UK Free Trade Agreement Sets Stage For Medtech Growth, But Industry Demands Safeguards

 
• By Shubham Singh

Announced after three years of negotiation, the FTA eliminates tariffs on 99% of Indian product types, covering nearly all trade value, and reduces tariffs on 90% of UK products. Although not yet formally signed, the deal is being positioned by the Indian government as “transformative,” with an estimated economic impact of $6.4bn for the UK alone by 2040.